Laura R Prakash
Overview
Explore the profile of Laura R Prakash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Doppenberg D, Stoop T, van Dieren S, Katz M, Janssen Q, Nasar N, et al.
Ann Surg Oncol
. 2024 Jan;
31(3):1919-1932.
PMID: 38170408
Introduction: About 25% of patients with localized pancreatic adenocarcinoma have non-elevated serum carbohydrate antigen (CA) 19-9 levels at baseline, hampering evaluation of response to preoperative treatment. Serum carcinoembryonic antigen (CEA)...
12.
Boyev A, Azimuddin A, Newhook T, Maxwell J, Prakash L, Bruno M, et al.
J Gastrointest Surg
. 2023 Nov;
27(12):2806-2814.
PMID: 37935998
Background: Risk-stratified drain fluid amylase cutoff values for postoperative day 1 (POD1) (DFA1) and POD3 (DFA3) can guide early drain removal after pancreatoduodenectomy (PD). The aim of this study was...
13.
Boyev A, Azimuddin A, Prakash L, Newhook T, Maxwell J, Bruno M, et al.
Ann Surg
. 2023 Oct;
279(6):1046-1053.
PMID: 37791481
Objective: Within a learning health system paradigm, this study sought to evaluate reasons for readmission to identify opportunities for improvement. Background: Post-pancreatectomy readmission rates have remained constant despite improved index...
14.
Boyev A, Prakash L, Chiang Y, Newhook T, Bruno M, Arvide E, et al.
Surg Oncol
. 2023 Sep;
51:101994.
PMID: 37742542
Background: The prognostic utility of Carbohydrate Antigen 19-9 (CA 19-9) and Carcinoembryonic Antigen (CEA) in ampullary adenocarcinoma is unclear. We sought to evaluate the association between initial tumor marker levels...
15.
Boyev A, Jain A, Newhook T, Prakash L, Chiang Y, Bruno M, et al.
JAMA Surg
. 2023 Sep;
158(11):e234154.
PMID: 37672236
Importance: Postoperative opioid overprescribing leads to persistent opioid use and excess pills at risk for misuse and diversion. A learning health system paradigm using risk-stratified pancreatectomy clinical pathways (RSPCPs) may...
16.
Boyev A, Prakash L, Chiang Y, Childers C, Jain A, Newhook T, et al.
J Gastrointest Surg
. 2023 Jul;
27(10):2135-2144.
PMID: 37468733
Background: Clinically relevant postoperative pancreatic fistula (CR-POPF) is a major source of morbidity after distal pancreatectomy. This study examined the association between postoperative opioid use and CR-POPF in the context...
17.
Boyev A, Arvide E, Newhook T, Prakash L, Bruno M, Dewhurst W, et al.
Ann Surg
. 2023 Jun;
279(4):657-664.
PMID: 37389897
Objective: The aim of this study was to compare infectious complications in pancreatoduodenectomy (PD) patients with biliary stents treated with short, medium, or long durations of prophylactic antibiotics. Background: Pre-existing...
18.
Liang T, Katz M, Prakash L, Chatterjee D, Wang H, Kim M, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370842
Neoadjuvant therapy (NAT) is increasingly used to treat patients with pancreatic ductal adenocarcinoma (PDAC). Patients with PDAC often show heterogenous responses to NAT with variable clinical outcomes, and the clinicopathologic...
19.
Tong Y, Lai Z, Katz M, Prakash L, Wang H, Chatterjee D, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37174073
Neoadjuvant FOLFIRINOX and gemcitabine/nab-paclitaxel (GemNP) therapies are increasingly used to treat patients with pancreatic ductal adenocarcinoma (PDAC). However, limited data are available on their clinicopathologic prognosticators. We examined the clinicopathologic...
20.
Ngo-Huang A, Parker N, Xiao L, Schadler K, Petzel M, Prakash L, et al.
Ann Surg
. 2023 Apr;
278(1):22-30.
PMID: 37026453
Objective: To determine the effects of a preoperative, home-based exercise program on fitness and physical function in patients with pancreatic cancer. Background: We previously established a well-tolerated preoperative exercise program...